Sanofi (NASDAQ: SNY) reported Q4 EPS of EUR1.66, EUR0.74 better than the analyst estimate of EUR0.92. Revenue for the quarter came in at EUR10.92 billion versus the consensus estimate of EUR12.65 billion.

GUIDANCE

Sanofi expects 2024 business EPS(1) to remain roughly stable excluding the impact of an expected effective tax rate increase to 21% and decrease low single-digit(2) at CER including the higher expected tax rate, barring unforeseen major adverse events. Applying average January 2024 exchange rates, the currency impact on 2024 business EPS is estimated between -3.5% to -4.5%.

For earnings history and earnings-related data on Sanofi (SNY) click here.